Table 2.
Baseline and sensitivity analysis characteristics of ZONDA patients before and after adjusting to SIRIUS patients for the analysis of percentage reduction in OCS dosage, percentage of patients with OCS elimination, and annual rate of clinically significant exacerbations
| Characteristics | ZONDAa (before adjusting) | SIRIUS (aggregate reported data) | ZONDA (after adjusting to SIRIUS) |
|---|---|---|---|
| Benralizumab 30 mg Q8W + placebo N = 148b | Mepolizumab 100 mg Q4W + placebo N = 135 | Base‐case ESS = 72 Sensitivity ESS = 44 | |
| Maintenance OCS dosage, prednisolone equivalent, mg/d | 14.21 (7.06) | 12.79 (6.74) | 12.79 (5.39) |
| Blood eosinophil count, cells/µL | 583.05 (478.99) | 380.73 (348.15) | 380.73 (278.68) |
| Exacerbations in the previous year | 2.78 (2.36) | 3.10 (3.10) | 3.10 (2.48) |
| Nasal polyps (%) | 32.43 | 24.50 | 24.50 |
| BMI, kg/m2 | 29.47 (5.94) | 28.66 (5.97) | 28.66 (4.78) |
| ACQ‐5 score | 2.69 (1.15) | 2.07 (1.22) | 2.07 (0.83) |
| History of omalizumab use (%) | 11.49 | 33 | 33 |
Data presented as mean (SD) unless otherwise indicated. Data in bold indicate variables used only in the sensitivity analysis.
Abbreviations: ACQ‐5: Asthma Control Questionnaire 5; BMI: body mass index; ESS: effective sample size; OCS: oral corticosteroid; Q4W: every 4 weeks; Q8W: every 8 weeks (first three doses Q4W); SD: standard deviation.
Data for the ZONDA population are calculated from individual patient data.
One patient was missing a baseline blood eosinophil count; six patients were missing information on 100% OCS reduction.